"Inflammation and arterial stiffness in humans"

Atherosclerosis

Volumn 237, Issue 2, 2014, Pages 381-390

  Jain, Snigdha ^a   Khera, Rohan ^a   Corrales Medina, Vicente F ^b   Townsend, Raymond R ^c   Chirinos, Julio A ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Arterial stiffness; Cardiovascular risk; Inflammation; Pulse wave velocity

Indexed keywords

ABATACEPT; ADALIMUMAB; ANTIINFLAMMATORY AGENT; BACTERIAL ANTIGEN; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETANERCEPT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; METHOTREXATE; MYELOPEROXIDASE; NITRIC OXIDE; PLACEBO; PREDNISONE; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STEROID; TETRAHYDROBIOPTERIN; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTERY ENDOTHELIUM; ATHEROSCLEROSIS; AUGMENTATION INDEX; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CAROTID ARTERY; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FAMILIAL MEDITERRANEAN FEVER; GASTRITIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE SYSTEM; IMMUNIZATION; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LOW FAT DIET; MEAN ARTERIAL PRESSURE; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK FACTOR; SALMONELLA TYPHI; SARCOIDOSIS; SMOOTH MUSCLE FIBER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; VACCINATION;

EID: 84908697888     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.09.011     Document Type: Review

References (94)

1. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001, 37(5):1236-1241.
2. Kelly R.P., Tunin R., Kass D.A. Effect of reduced aortic compliance on cardiac efficiency and contractile function of in situ canine left ventricle. Circ. Res. 1992, 71(3):490-502.
3. O'Rourke M.F., Safar M.E. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005, 46(1):200-204.
4. Mäki-Petäjä K.M., Wilkinson I.B. Inflammation and large arteries: potential mechanisms for inflammation-induced arterial stiffness. Artery Res. 2012, 6(2):59-64.
5. Blacher J., Guerin A.P., Pannier B., Marchais S.J., Safar M.E., London G.M. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999, 99(18):2434-2439.
6. Boutouyrie P., Tropeano A.I., Asmar R., et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002, 39(1):10-15.
7. Cruickshank K., Riste L., Anderson S.G., Wright J.S., Dunn G., Gosling R.G. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002, 106(16):2085-2090.
8. Willum-Hansen T., Staessen J.A., Torp-Pedersen C., et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113(5):664-670.
9. Chirinos J.A. Arterial stiffness: basic concepts and measurement techniques. J.Cardiovasc. Transl. Res. 2012, 5(3):243-255.
10. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
11. Aznaouridis K.A., Stefanadis C.I. Inflammation and arterial function. Artery Res. 2007, 1(1):32-38.
12. Park S., Lakatta E.G. Role of inflammation in the pathogenesis of arterial stiffness. Yonsei Med. J. 2012, 53(2):258-261.
13. Wykretowicz A., Guzik P., Kasinowski R., et al. Augmentation index, pulse pressure amplification and superoxide anion production in patients with coronary artery disease. Int. J. Cardiol. 2005, 99(2):289-294.
14. Wilkinson I.B., Qasem A., McEniery C.M., Webb D.J., Avolio A.P., Cockcroft J.R. Nitric oxide regulates local arterial distensibility invivo. Circulation 2002, 105(2):213-217.
15. Wilkinson I.B., MacCallum H., Cockcroft J.R., Webb D.J. Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity invivo. Br. J. Clin. Pharmacol. 2002, 53(2):189-192.
16. Stewart A.D., Millasseau S.C., Kearney M.T., Ritter J.M., Chowienczyk P.J. Effects of inhibition of basal nitric oxide synthesis on carotid-femoral pulse wave velocity and augmentation index in humans. Hypertension 2003, 42(5):915-918.
17. Gunnett C.A., Lund D.D., McDowell A.K., Faraci F.M., Heistad D.D. Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction. Arterioscler. Thromb. Vasc. Biol. 2005, 25(8):1617-1622.
18. Yoshizumi M., Perrella M.A., Burnett J.C., Lee M.E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ. Res. 1993, 73(1):205-209.
19. Rabelink T.J., Luscher T.F. Endothelial nitric oxide synthase: host defense enzyme of the endothelium?. Arterioscler. Thromb. Vasc. Biol. 2006, 26(2):267-271.
20. Xu J., Xie Z., Reece R., Pimental D., Zou M.H. Uncoupling of endothelial nitric oxidase synthase by hypochlorous acid: role of NAD(P)H oxidase-derived superoxide and peroxynitrite. Arterioscler. Thromb. Vasc. Biol. 2006, 26(12):2688-2695.
21. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106(12):1439-1441.
22. Ushio-Fukai M., Alexander R.W., Akers M., et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J.Biol. Chem. 1999, 274(32):22699-22704.
23. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases invitro. Implications for atherosclerotic plaque stability. J.Clin. Invest. 1996, 98(11):2572-2579.
24. Delles C., Zimmerli L.U., McGrane D.J., et al. Vascular stiffness is related to superoxide generation in the vessel wall. J.Hypertens. 2008, 26(5):946-955.
25. Al-Benna S., Hamilton C.A., McClure J.D., et al. Low-density lipoprotein cholesterol determines oxidative stress and endothelial dysfunction in saphenous veins from patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26(1):218-223.
26. Guzik T.J., West N.E., Black E., et al. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 2000, 86(9):E85-E90.
27. Montero I., Orbe J., Varo N., et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J.Am. Coll. Cardiol. 2006, 47(7):1369-1378.
28. Dzau V.J., Braun-Dullaeus R.C., Sedding D.G. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. 2002, 8(11):1249-1256.
29. Chai S., Chai Q., Danielsen C.C., et al. Overexpression of hyaluronan in the tunica media promotes the development of atherosclerosis. Circ. Res. 2005, 96(5):583-591.
30. Kaji T., Hiraga S., Yamamoto C., et al. Tumor necrosis factor alpha-induced alteration of glycosaminoglycans in cultured vascular smooth-muscle cells. Biochim. Biophys. Acta 1993, 1176(1-2):20-26.
31. Galis Z.S., Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 2002, 90(3):251-262.
32. Zieman S.J., Melenovsky V., Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25(5):932-943.
33. Yasmin, McEniery C.M., Wallace S., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005, 25(2):372.
34. Vlachopoulos C., Aznaouridis K., Dima I., et al. Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults. Int. J. Cardiol. 2007, 122(3):232-238.
35. Maki J.M., Rasanen J., Tikkanen H., et al. Inactivation of the lysyl oxidase gene lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation 2002, 106(19):2503-2509.
36. Rodriguez C., Alcudia J.F., Martinez-Gonzalez J., Raposo B., Navarro M.A., Badimon L. Lysyl oxidase (LOX) down-regulation by TNFalpha: a new mechanism underlying TNFalpha-induced endothelial dysfunction. Atherosclerosis 2008, 196(2):558-564.
37. Moe S.M., Chen N.X. Inflammation and vascular calcification. Blood Purif. 2005, 23(1):64-71.
38. Schnabel R., Larson M.G., Dupuis J., et al. Relations of inflammatory biomarkers and common genetic variants with arterial stiffness and wave reflection. Hypertension 2008, 51(6):1651-1657.
39. Yasmin, McEniery C.M., Wallace S., Mackenzie I.S., Cockcroft J.R., Wilkinson I.B. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler. Thromb. Vasc. Biol. 2004, 24(5):969-974.
40. Mattace-Raso F.U., van der Cammen T.J., van der Meer I.M., et al. C-reactive protein and arterial stiffness in older adults: the Rotterdam study. Atherosclerosis 2004, 176(1):111-116.
41. Lieb W., Larson M.G., Benjamin E.J., et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart study. Circulation 2009, 119(1):37-43.
42. Johansen N.B., Vistisen D., Brunner E.J., et al. Determinants of aortic stiffness: 16-year follow-up of the Whitehall II study. PloS One 2012, 7(5):e37165.
43. McEniery C.M., Spratt M., Munnery M., et al. An analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up from the Caerphilly prospective study. Hypertension 2010, 56(1):36-43.
44. van Bussel B.C., Schouten F., Henry R.M., et al. Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period. Hypertension 2011, 58(4):588-595.
45. Jae S.Y., Heffernan K.S., Yoon E.S., et al. Pulsatile stress, inflammation and change in arterial stiffness. J.Atheroscler. Thromb. 2012, 19(11):1035-1042.
46. Tomiyama H., Hashimoto H., Tanaka H., et al. Continuous smoking and progression of arterial stiffening: a prospective study. J.Am. Coll. Cardiol. 2010, 55(18):1979-1987.
47. Maki-Petaja K.M., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006, 114(11):1185-1192.
48. Shang Q., Tam L.S., Li E.K., Yip G.W., Yu C.M. Increased arterial stiffness correlated with disease activity in systemic lupus erythematosus. Lupus 2008, 17(12):1096-1102.
49. Cypiene A., Laucevicius A., Venalis A., et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin. Rheumatol. 2008, 27(12):1517-1522.
50. Pieringer H., Stuby U., Pohanka E., Biesenbach G. Arterial stiffness in a muscular artery in women with longstanding rheumatoid arthritis compared with healthy controls and patients with traditional cardiovascular risk factors. Rheumatol. Int. 2010, 30(10):1335-1339.
51. Yildiz M., Yildiz B.S., Soy M., Tutkan H. Impairment of arterial distensibility in premenopausal women with systemic lupus erythematosus. Kardiol. Pol. 2008, 66(11):1194-1199. (discussion 1200-1191).
52. Mathieu S., Joly H., Baron G., et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology 2008, 47(8):1203-1207.
53. Wallberg-Jonsson S., Caidahl K., Klintland N., Nyberg G., Rantapaa-Dahlqvist S. Increased arterial stiffness and indication of endothelial dysfunction in long-standing rheumatoid arthritis. Scand. J. Rheumatol. 2008, 37(1):1-5.
54. Tam L.S., Shang Q., Li E.K., et al. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis - a randomized trial. J.Rheumatol. 2012, 39(12):2267-2275.
55. Wong M., Oakley S.P., Young L., et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68(8):1277-1284.
56. Kume K., Amano K., Yamada S., Hatta K., Ohta H., Kuwaba N. Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial. J.Rheumatol. 2011, 38(10):2169-2171.
57. I. McInnes, J.S. Lee, L. Thompson, etal. The Effects of Tocilizumab Treatment on Lipids and Inflammatory/Prothrombotic Markers in Patients with Rheumatoid Arthritis: Data from the Randomised, Controlled MEASURE Study.
58. Maki-Petaja K.M., Elkhawad M., Cheriyan J., et al. Anti-tumor necrosis factor-alpha therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012, 126(21):2473-2480.
59. Angel K., Provan S.A., Fagerhol M.K., Mowinckel P., Kvien T.K., Atar D. Effect of 1-year anti-TNF-alpha therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am. J. Hypertens. 2012, 25(6):644-650.
60. Pieringer H., Stuby U., Pohanka E., Biesenbach G. Augmentation index in patients with rheumatoid arthritis and ankylosing spondylitis treated with infliximab. Clin. Rheumatol. 2010, 29(7):723-727.
61. Galarraga B., Khan F., Kumar P., Pullar T., Belch J.J. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. Rheumatology 2009, 48(11):1418-1423.
62. Mathieu S., Couderc M., Glace B., et al. Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics 2013, 7:259-264.
63. Van Doornum S., McColl G., Wicks I.P. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. Rheumatology 2005, 44(11):1428-1432.
64. Komai N., Morita Y., Sakuta T., Kuwabara A., Kashihara N. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. Mod. Rheumatol Jpn. Rheum. Assoc. 2007, 17(5):385-390.
65. Mathieu S., Pereira B., Couderc M., Rabois E., Dubost J.J., Soubrier M. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology 2013, 52(1):204-209.
66. Capkin E., Karkucak M., Kiris A., et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology 2012, 51(5):910-914.
67. Schillaci G., Bartoloni E., Pucci G., et al. Aortic stiffness is increased in polymyalgia rheumatica and improves after steroid treatment. Ann. Rheum. Dis. 2012, 71(7):1151-1156.
68. Pieringer H., Stuby U., Hargassner S., Biesenbach G. Treatment with corticosteroids reduces arterial stiffness in patients with polymyalgia rheumatica as measured with pulse wave analysis. Ann. Rheum. Dis. 2008, 67(2):279.
69. Meng X., Qie L., Wang Y., Zhong M., Li L. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin. Invest Med. Med. Clin. Exp. 2009, 32(6):E238.
70. Hongo M., Tsutsui H., Mawatari E., et al. Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia: a 5-year follow-up study. Circ. J. Off. J. Jpn. Circ. Soc. 2008, 72(5):722-728.
71. Pirro M., Schillaci G., Mannarino M.R., et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr. Metabol. Cardiovasc. Dis. NMCD 2007, 17(6):436-441.
72. Yokoyama H., Kawasaki M., Ito Y., Minatoguchi S., Fujiwara H. Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity. J.Am. Coll. Cardiol. 2005, 46(11):2031-2037.
73. Ichihara A., Hayashi M., Koura Y., Tada Y., Kaneshiro Y., Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J.Hum. Hypertens. 2005, 19(2):103-109.
74. Kurpesa M., Tyminski M., Trzos E., Kidawa M., Krzeminska-Pakula M. Influence of prolonged statin therapy on the arterial distensibility in stable ischemic heart disease. Przeglad Lek. 2005, 62(4):210-213.
75. Orr J.S., Dengo A.L., Rivero J.M., Davy K.P. Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension 2009, 54(4):763-768.
76. Ferrier K.E., Muhlmann M.H., Baguet J.P., et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J.Am. Coll. Cardiol. 2002, 39(6):1020-1025.
77. Maki-Petaja K.M., Booth A.D., Hall F.C., et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J.Am. Coll. Cardiol. 2007, 50(9):852-858.
78. Raison J., Rudnichi A., Safar M.E. Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study. J.Hum. Hypertens. 2002, 16(10):705-710.
79. Fassett R.G., Robertson I.K., Ball M.J., Geraghty D.P., Sharman J.E., Coombes J.S. Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial. J.Atheroscler. Thromb. 2010, 17(3):235-241.
80. Ichihara A., Hayashi M., Ryuzaki M., Handa M., Furukawa T., Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 2002, 17(8):1513-1517.
81. Wang Z.G., Chen B.W., Lu N.Q., Cheng Y.M., Dang A.M. Relationships between use of statins and arterial stiffness in normotensive and hypertensive patients with coronary artery disease. Chin. Med. J. 2013, 126(16):3087-3092.
82. Timar O., Szekanecz Z., Kerekes G., et al. Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immuncomplex production in patients with systemic sclerosis-a prospective case-series study. Arthritis Res. Ther. 2013, 15(5):R105.
83. Efrati S., Averbukh M., Dishy V., Faygenzo M., Friedensohn L., Golik A. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers. Eur. J. Clin. Pharmacol. 2007, 63(2):113-121.
84. Muramatsu J., Kobayashi A., Hasegawa N., Yokouchi S. Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997, 130(1-2):179-182.
85. Lee J.M., Wiesmann F., Shirodaria C., et al. Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging. Atherosclerosis 2008, 197(2):951-958.
86. Stojakovic T., Claudel T., Putz-Bankuti C., et al. Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 2010, 209(1):178-183.
87. Kontopoulos A.G., Athyros V.G., Pehlivanidis A.N., Demitriadis D.S., Papageorgiou A.A., Boudoulas H. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr. Med. Res. Opin. 2003, 19(1):22-27.
88. Shinohara K., Shoji T., Kimoto E., et al. Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus. J.Atheroscler. Thromb. 2005, 12(4):205-210.
89. Matsuo T., Iwade K., Hirata N., et al. Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia. Heart Vessels 2005, 20(1):8-12.
90. Jae S.Y., Yoon E.S., Jung S.J., et al. Effect of cardiorespiratory fitness on acute inflammation induced increases in arterial stiffness in older adults. Eur. J. Appl. Physiol. 2013, 113(8):2159-2166.
91. Wallace S.M., Maki-Petaja K.M., Cheriyan J., et al. Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction. Br. J. Clin. Pharmacol. 2010, 70(6):799-806.
92. Redheuil A., Yu W.C., Wu C.O., et al. Reduced ascending aortic strain and distensibility: earliest manifestations of vascular aging in humans. Hypertension 2010, 55(2):319-326.
93. Ikonomidis I., Lekakis J.P., Nikolaou M., et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation 2008, 117(20):2662-2669.
94. Protogerou A.D., Zampeli E., Fragiadaki K., Stamatelopoulos K., Papamichael C., Sfikakis P.P. Apilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis 2011, 219(2):734-736.